Form 4: Carisma Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Marella Thorell, a director of Carisma Therapeutics Inc., acquired stock options on July 1, 2024.
Summary
- Marella Thorell, a director of Carisma Therapeutics Inc., filed a Form 4 on July 1, 2024.
- The form reports a transaction where Thorell acquired stock options.
- Thorell acquired options to purchase 38,700 shares of common stock at an exercise price of $1.67 per share.
- The options vest over three years in equal monthly installments starting July 1, 2024, contingent upon continued service to Carisma Therapeutics Inc.
- The options expire on July 1, 2034.
- Following the transaction, Thorell directly owns options for 38,700 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of earliest transaction (acquisition of stock options) and effective date of vesting. |
| 07/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.